Clinical trials: Inoperable Disease
Carcinoma, Non-Small-Cell Lung
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA…
- Trial name
- NCT02343952
- Testing
- Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 93 people
- Sponsor
- Nasser Hanna, M.D.
Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
This is a clinical trial with a crossover design to determine patients' preference for capecitabine in combination with bevacizumab or everolimus in combination with exemestane for advanced breast cancer patients and to evaluate…
- Conditions
- Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
- Trial name
- IMPROVE (NCT02248571)
- Testing
- Bevacizumab, Capecitabine, Everolimus
- Where
- Germany
- Volunteers
- 85 people
- Sponsor
- iOMEDICO AG
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
This phase I/II trial studies the side effects and best dose of vorinostat when given together with paclitaxel and radiation therapy and to see how well it works in treating patients unable to tolerate cisplatin with stage III…
- Trial name
- NCT00662311
- Testing
- vorinostat, paclitaxel, radiation therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
This is a multi-center, non-interventional, study with the aim to access routine practice of diagnostic and treatment approaches in patients with NSCLC and SCLC in 50 largest oncology centers in Russian Federation.
- Trial name
- PASSAT (NCT05887011)
- Where
- 37 sites in Russia
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Esophageal Cancer
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma. Aim to find the difference in efficacy and safety between tirilizumab combined with concurrent chemoradiation…
- Trial name
- TCRTOE (NCT06061146)
- Testing
- Arm A, Arm B
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer
Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Radiofrequency ablation uses a high-frequency electric current to kill tumor cells. External-beam radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00499447
- Testing
- radiofrequency ablation, radiation therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Wake Forest University Health Sciences
Melanoma
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
Study 1501-852A is a Phase 1 Study with the objective of determining safety and the highest tolerated dose of an immune response modifier cream directly applied to advanced, inoperable, melanoma skin lesions.
- Trial name
- NCT00091689
- Testing
- 852A
- Where
- 2 sites in United States
- Sponsor
- Pfizer
Intestinal Obstruction
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
The primary objective of the study is to evaluate the impact on quality of life of Lanreotide Autogel 120 mg in combination with standard care, in comparison to the standard care alone, in subjects affected by inoperable…
- Trial name
- QoL in IMBO (NCT02365584)
- Testing
- lanreotide (Autogel formulation)
- Where
- 13 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Ipsen
Breast Cancer
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
- Trial name
- NCT00166543
- Testing
- TAS-108
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- SRI International
Melanoma
Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma
This is a Phase II, non-randomized, open label study of ILX651 in patients with inoperable locally advanced or metastatic melanoma. Approximately 60 patients will be enrolled in this study that is expected to last 18 months.
- Trial name
- NCT00068211
- Testing
- ILX651
- Where
- 19 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
This is a 2-part study in patients with epidermal growth factor receptor mutation positive (EGFRm+) non-small cell lung cancer (NSCLC) whose disease has progressed on treatment with an epidermal growth factor receptor…
- Trial name
- NCT02163733
- Testing
- AZD9291 tablets, Pharmacokinetic sampling - AZD9291, Dietary Fasted
- Where
- 13 sites in France, South Korea and 2 more
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Melanoma
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
This study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab.
- Trial name
- NCT02796352
- Testing
- High dose bolus interleukin-2 (HD IL2)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ahmad Tarhini
Breast Cancer
HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy
This observational study will evaluate the efficacy, safety and patient reported quality of life of palliative first-line Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) in patients with HER2-positive advanced…
- Trial name
- NCT01777958
- Where
- Germany
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular Carcinoma
This phase II study is to evaluate the effectiveness of hypofractionated proton beam therapy (PBT) for Hepatocellular Carcinoma patients in hepatitis B endemic area.
- Trial name
- NCT02395523
- Testing
- Proton Beam Therapy
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- National Cancer Center, Korea
Pancreatic Cancer
Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer
Pancreatic cancer is an aggressive disease with an extremely poor prognosis. It is the forth leading cause of cancer-related fatalities, with an estimated one-year and five-year survival rate of 21% and 5%, respectively.
- Trial name
- NCT00486460
- Testing
- Gemcitabine, Curcumin, Celebrex
- Where
- Israel
- Sponsor
- Tel-Aviv Sourasky Medical Center
Thyroid Cancer
Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer
To determine the efficacy and safety of intensity modulated radiation therapy combined with apatinib for inoperable or iodine refractory thyroid cancer.
- Trial name
- NCT03300765
- Testing
- Apatinib, Intensity modulated radiation therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xiayun He, MD
Carcinoma, Non-Small-Cell Lung
GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)
To examine the safety and efficacy of telomerase peptide vaccination ( stimulation of the immune system) in patients with NSCLC after having been treated with conventional therapy with radiotherapy and docetaxel as a…
- Trial name
- NCT00509457
- Testing
- GV 1001 Telomerase peptide
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Gastric Cancer, Gastroesophageal Junction Cancer
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of the combination of Cisplatin,5-Fluorouracil(5FU) and Afatinib as first-line therapy in patients with advanced gastric or gastroesophageal junction cancer.
- Trial name
- A-GAPP (NCT01743365)
- Testing
- Cisplatin-5FU-Afatinib
- Where
- 15 sites in Greece
- Volunteers
- 55 people
- Sponsor
- Hellenic Cooperative Oncology Group
Melanoma
PD-L1 PET Imaging in Melanoma Patients
This is a feasibility study for the use of [18F]PD-L1 as a PET tracer that will be conducted in a single center. The study consists of two phases.
- Trial name
- NCT03520634
- Testing
- PD-L1 PET imaging
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Early Stage Non-small Cell Lung Cancer
CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer
This study observes the efficacy and side effects of CT-guided radioactive iodine-125 seed brachytherapy in inoperable early stage non-small cell lung cancer retrospectively, and analyzes the influence of clinical and dosimetric…
- Trial name
- NCT03916367
- Testing
- CT-guided Radioactive I-125 Seeds Implantation
- Volunteers
- 39 people
- Sponsor
- Peking University Third Hospital